BioSim™ anti-Secukinumab (Human) ELISA Kit

(No reviews yet) Write a Review
Usually Shipped in 5 Working Days
96 Assays
Storage Conditions:
Shipping Conditions:
Gel Pack
Shelf life:
12 months
Frequently bought together:


Secukinumab is a human IgG1 monoclonal antibody that targets IL-17α and prevents its association with the receptor IL-17R. This results in decreased release of proinflammatory cytokines and chemokines and downregulation of inflammation. IL-17 represents a family of cytokines (IL-17 A-F) released by T-helper-17 (Th17) cells, mast cells, neutrophils, and dendritic cells and promotes inflammation. Studies show that IL-17 is associated with multiple autoimmune diseases such as rheumatoid arthritis, spondyloarthritis, psoriasis, Crohn's disease, and multiple sclerosis. The original monoclonal antibody received approval from the FDA to treat plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, upon administration of the antibody, patients tend to develop an immune response that results in the formation of anti-Secukinumab antibodies, thus adversely affecting the therapeutic response to treatment. BioSim™ anti-Secukinumab ELISA kit qualitatively measures antibodies to Secukinumab in human serum or plasma samples. The kit is based on the Sandwich ELISA principle. Standards and samples (serum or plasma) are added to the microtiter plate coated with Secukinumab. After incubation, the wells are washed. The HRP conjugated probe is added and binds to the antibodies to Secukinumab that is captured by Secukinumab coated on the wells. Following incubation, wells are washed and the enzymatic activity is detected by the addition of TMB chromogen substrate. Finally, the reaction is terminated with an acidic stop solution. The color developed is proportional to the amount of antibodies to Secukinumab in the sample or standard. The qualitative test results can be evaluated using cut-off values.

Alternate Name: IL17, CTLA8, IL-17, CTLA-8, IL17A

Tag Line: A Sandwich ELISA kit for the Qualitative measurement of antibodies to Secukinumab in serum or plasma samples

Summary: N/A

Detection Method: Absorbance (450 nm)

Sample Type: Plasma Serum

Species Reactivity: Human

Applications: Sandwich ELISA kit used for in vitro Qualitative determination of antibodies to Secukinumab in human serum and plasma samples

Features & Benefits: For in vitro Qualitative determination of antibodies to Secukinumab in human serum and plasma samples Cross Reactivity: Except for Secukinumab, there is no cross reaction with other therapeutic antibodies and native serum immunoglobins Assay Precision: Intra-Assay and Inter-Assay CV < 30%

View AllClose